Abstract 453P
Background
Obesity is a risk factor for the development of new cases of breast cancer and also affects survival in women who have already been diagnosed with breast cancer, but in Asian women, these findings is not evident. We aimed to investigate the correlation between the body mass index (BMI) and overall survival of patients with a breast cancer.
Methods
We conducted a retrospective observational study from a single institute from January 2014 to December 2018. Among all 412 patients diagnosed and treated with breast cancer, we categorized them as three groups (low weight: BMI < 18kg/m2, normal: BMI < 25kg/m2, obesity: BMI ≥25kg/m2) and investigated overall survival according to menopausal status and adjuvant endocrine therapy. We used a kaplan-meier analysis with log-rank test.
Results
Total 412 patients were enrolled. Mean duration of follow up was 33.3 months. Obesity, normal BMI and low BMI was 120(29.1%), 202(49.0%), and 40 (9.7%) patients, respectively. BMI was correlated with age, patients with obesity was 16% (28/174) of women with less than 50 years, but 38.6% (92/238) of women with more than 50 years. Overall survival was not significantly different among groups (Obesity group: 95%, Normal group: 95.5%, low BMI: 97.5%, p = 0.77, χ2=1.1). Women without adjuvant hormone therapy show lower overall survival, but it is not significant (Obesity group: 87.7%, Normal group: 94.4%, low BMI: 90%, p = 0.89, χ2=0.62). In women with more than 50 years, low BMI was better than normal to obese women (p = 0.89, χ2=0.6).
Conclusions
Obesity is not major risk factor of overall survival in Korea, but in hormone receptor negative breast cancers, it correlated with early onset death or recurrence. Not only further studies need to lighten the relationship between obesity and long-term survival, but also intervention to reduce BMI needs to know its effects on breast cancer survival in Korea.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract